Nightingale Health Shortlisted for Finnish Health Awards 2018

Nightingale Health has been nominated as a "Health Innovation" of the year finalist for the Health Awards 2018, an annual event focusing on the future vision of Finnish healthcare. Nightingale will participate in the awards ceremony, held in Helsinki, as part of the Foresight Forum in January 2018.

"We're proud to have received recognition from the Health Awards jury for our impact on the current debate taking place in the Finnish healthcare sector. As innovators in the healthcare space we aim to switch the primary strategy of the current system from disease treatment to disease prevention, replacing routinely used cholesterol tests worldwide," says Teemu Suna (CEO and Founder, Nightingale Health).

Nightingale's service provides health data from blood biomarker analysis, assisting clinicians in providing more personalized guidance to patients. In the long-term, Nightingale plans to fully integrate its service into healthcare systems and provide tools for patients to follow-up their own health, enabling preventive healthcare for chronic diseases, such as diabetes and cardiovascular disease. Earlier this year, Nightingale was selected as one of the winners of MIT's (Massachusetts's Institute of Technology) Solve competition, hosted at the United Nations HQ. In November 2017, Nightingale was awarded as one of the most innovative biotech SMEs in Europe.

The Health Awards is a recognized annual competition and event carried out by Tamro and the Finnish health industry. The Health Awards & Foresight Forum 2018 aims to bring together contributors, decision makers, companies and innovators in the healthcare and wellbeing sector.

Teemu Suna, CEO, Founder & Chairman
Nightingale Health
teemu.suna@nightingalehealth.com
+358 40 196 1669

About Nightingale Health

Nightingale Health Ltd. is the innovator of an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis assay for early disease detection. Our aim is to solve the growing burden of cardiovascular disease and diabetes, accounting for healthcare costs of over 1.6 trillion dollars annually. Our pioneering precision medicine services, include: effective chronic disease screening, health diagnostics and improving treatment efficacy. By providing our customers with accurate health data, we plan to help empower patients to follow-up on their own well-being and take proactive steps to stay healthy.

For more information, please visit https://www.nightingalehealth.com